Company Profile
Longeveron Stock Price, News & Catalysts
- Ticker:
- LGVN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.84 USD (+2.02%)
Close
Last updated: August 21, 2026
24M USD
Market cap
Why the stock is moving
The latest monitored company update is “Longeveron Announces 1-for-10 Reverse Stock Split.” The corresponding closing-price reaction is not yet available.
Company overview
Regenerative Medicine Company
Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
Laromestrocel
Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors.
Hypoplastic Left Heart Syndrome
The ELPIS program evaluates laromestrocel as an adjunct to staged surgery in infants with hypoplastic left heart syndrome, an orphan pediatric condition.
Additional Regenerative Applications
The company is also exploring laromestrocel in aging-related and neurological conditions where inflammation and impaired tissue repair may contribute to disease.
Future catalysts
- Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Longeveron (LGVN)?
Longeveron (LGVN) most recently closed at 0.84 USD, a +2.02% move versus the previous session.
What is the market cap of Longeveron (LGVN)?
Longeveron currently has a market capitalization of 24M USD on BioPharmSignal.
What does Longeveron do?
Regenerative Medicine Company Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions. Laromestrocel Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors. Hypoplastic Left Heart Syndrome The ELPIS program evaluates...
On which exchange is LGVN stock listed?
Longeveron (LGVN) is associated with NASDAQ, United States, Biopharma.
What is Regenerative?
Regenerative Medicine Company Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
Which conditions is Longeveron targeting with Regenerative?
Longeveron is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Longeveron describe recent progress with Regenerative?
Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.
What is Medicine?
Regenerative Medicine Company Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.